Cell Regeneration Medicine Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The cell regeneration medicine market size has grown rapidly in recent years. It will grow from $41.83 billion in 2024 to $48.25 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to aging population, prevalence of chronic diseases, growing government and corporate funding, growing demand for functional regenerative medicine products.

The cell regeneration medicine market size is expected to see rapid growth in the next few years. It will grow to $82.68 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising demand for regenerative medicine products from the horeca sector, shortage of organs for transplantation, increasing r&d activities, growing demand for gene therapies. Major trends in the forecast period include advanced therapies, clinical trial expansion, tissue engineering and 3d bioprinting, exosome-based therapies, personalized medicine.

The extensive adoption of organ transplantation is anticipated to drive the growth of the cell regeneration medicine market in the foreseeable future. Organ transplantation is a medical procedure involving the removal of an organ from one individual's body and its placement into the body of a recipient to replace a damaged or missing organ. This medical practice has gained significant popularity due to its ability to extend lives and reduce the need for interventions like dialysis. Cell regenerative medicine holds the promise of advancing organ transplantation by focusing on the repair and regeneration of damaged tissues or organs. For instance, in January 2023, as reported by the United Network for Organ Sharing, a US-based organization specializing in scientific and educational initiatives, the United States witnessed approximately 42,887 organ transplant procedures in 2022, marking a 3.7% increase compared to 2021. Consequently, the widespread acceptance of organ transplants is poised to be a driving force behind the cell regeneration medicine market.

The increasing prevalence of chronic diseases is expected to drive the growth of the cell regeneration medicine market in the coming years. Chronic diseases are illnesses that persist for three months or longer and tend to worsen over time. Cell regeneration medicine offers promising potential for treating chronic diseases by introducing innovative methods to repair and rejuvenate damaged tissues and organs, creating new opportunities for research and therapies that could revolutionize chronic disease management. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported an age-standardized death rate due to chronic conditions of 448 per 100,000 population in 2020, which rose to 459 per 100,000 in 2021, and further to 490 per 100,000 in 2022. Consequently, the increasing burden of chronic diseases is fueling the growth of the cell regeneration medicine market.

Leading companies in the cell regeneration medicine market are focusing on the development of medical-grade bioink to enhance their competitive position. Medical-grade bioink is a specialized ink designed for bioprinting that adheres to strict regulatory standards for safety and biocompatibility, making it ideal for use in tissue engineering, regenerative medicine, and creating biological structures for medical applications. For example, in October 2023, CELLINK, a Sweden-based company known for its innovations in cell regeneration medicine, introduced CELLINK Vivoink. This is the first medical-grade bioink created specifically for clinical applications in regenerative medicine and tissue engineering, optimized for exceptional printability, mechanical stability, and cell viability.

In April 2022, Metcela Inc., a Japanese biotechnology firm with expertise in heart disease treatment, completed the acquisition of Japan Regenerative Medicine Co. Ltd. (JRM) for an undisclosed sum. This acquisition provides Metcela with the opportunity to diversify and enhance its product development portfolio through the addition of JRM-001. This innovative product utilizes cardiac stem cells to facilitate the restoration of cardiac tissues, particularly for the treatment of heart diseases. Japan Regenerative Medicine Co. Ltd. (JRM) is a Japanese biotechnology company primarily focused on the development of regenerative medicine solutions for heart diseases.

Major companies operating in the cell regeneration medicine market are Pfizer Inc., Johnson & Johnson, F.Hoffman-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Medtronic PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., ViaCord LLC, Stryker Corporation, Zimmer Biomet Holdings Inc., Cook Biotech Inc., Integra LifeSciences Holdings Corporation, NuVasive Inc., Organogenesis Holdings Inc., AMAG Pharmaceuticals Inc., Takara Bio Inc., MiMedx Group Inc., Vericel Corporation, Mesoblast Limited, Osiris Therapeutics Inc., Guanhao Biotech Co. Ltd., CordLife Group Limited, FUJIFILM Cellular Dynamics Inc., Cesca Therapeutics Inc., U.S. Stem Cell Inc., Cytori Therapeutics Inc.

North America was the largest region in the cell regeneration medicine market in 2024. The regions covered in cell regeneration medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell regeneration medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cell regeneration medicine market includes revenues earned by entities by providing stem cell treatments, cartilage regeneration, platelet-rich plasma and tissue engineering. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell regeneration medicine market also includes of sales of various types of cell regeneration medicines, such as stem cells and progenitor cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Cell regeneration medicine is a field within medical science and technology that centers on harnessing the inherent capacity of cells to mend, replace, and regenerate damaged or ailing tissues and organs within the human body. This discipline employs diverse cellular therapies, tissue engineering techniques, and regenerative medicine strategies to facilitate healing and reinstate functionality to compromised areas.

The key components of cell regeneration medicine encompass therapeutics, tools, banks, and services. Therapeutics pertain to the medical treatment and care of patients with the objective of both preventing and managing diseases, alleviating pain or injury, and addressing conditions like injuries and diseases through methods such as immunomodulation therapy and tissue engineering. These therapeutics are classified into specific categories, including dermatology, musculoskeletal, immunology and inflammation, oncology, cardiovascular, ophthalmology, and others. They find application across various sectors, serving end-users like hospitals and clinics, commercial industries, government institutions, and academic research institutes.

The cell regeneration medicine research report is one of a series of new reports that provides cell regeneration medicine market statistics, including the cell regeneration medicine global market size, regional shares, competitors with a cell regeneration medicine market share, detailed cell regeneration medicine market segments, market trends and opportunities and any further data you may need to thrive in the cell regeneration medicine industry. This cell regeneration medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.